<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04187638</url>
  </required_header>
  <id_info>
    <org_study_id>HLS-JLG-OOstudy</org_study_id>
    <nct_id>NCT04187638</nct_id>
  </id_info>
  <brief_title>Effect of Olive Oil Consumption on Cardiovascular Biomarkers</brief_title>
  <official_title>Effect of Olive Oil Consumption on Cardiovascular Biomarkers in Asians and Caucasians: A Randomized, Crossover, Controlled Interventional Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northumbria University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northumbria University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main aim of this study is to examine the effect of olive oil consumption on several
      cardiovascular risk markers between Caucasians and Asian ethnicity. The primary assessments:
      endothelial function's biomarkers: cell and vascular adhesion molecules (ICAMs and VCAMs) and
      nitric oxide (NO). The secondary assessments: Lipid profile.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 31, 2019</start_date>
  <completion_date type="Anticipated">August 1, 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>A randomized, double‐blind, placebo‐controlled crossover trial.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>changes in ambulatory blood pressure</measure>
    <time_frame>Baseline and 2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in plasma total cholesterol</measure>
    <time_frame>Baseline and 2 weeks</time_frame>
    <description>Plasma total cholesterol vascular cell adhesion molecule 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Intercellular Adhesion Molecule 1</measure>
    <time_frame>Baseline and 2 weeks</time_frame>
    <description>Plasma levels of Intercellular Adhesion Molecule 1 measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in vascular cell adhesion molecule 1</measure>
    <time_frame>Baseline and 2 weeks</time_frame>
    <description>Plasma levels of vascular cell adhesion molecule 1 measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in C-reactive protein</measure>
    <time_frame>Baseline and 2 weeks</time_frame>
    <description>Plasma levels of CRP measured</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Cardiovascular Risk Factor</condition>
  <arm_group>
    <arm_group_label>Olive oil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 30ml/day of olive oil for two weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Butter</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive 30g/day of butter also for two weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Olive oil</intervention_name>
    <description>Participants will be randomly allocated to receive daily dose of 30ml of olive oil (OO) as intervention group or a matching control (butter 30g) for 2 weeks each (i.e. two weeks olive oil and two weeks butter), separated by a washout period of 2 weeks between treatments.</description>
    <arm_group_label>Butter</arm_group_label>
    <arm_group_label>Olive oil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Butter</intervention_name>
    <description>Participants will be randomly allocated to receive daily dose of 30ml of olive oil (OO) as intervention group or a matching control (butter 30g) for 2 weeks each (i.e. two weeks olive oil and two weeks butter), separated by a washout period of 2 weeks between treatments.</description>
    <arm_group_label>Butter</arm_group_label>
    <arm_group_label>Olive oil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Male

        Orient Asians (including Chinese, Japanese, Korean, and Malaysia Chinese) and Caucasians

        Age 18‐70 years

        Self‐reported in good general health

        Exclusion Criteria:

        Female

        Age older than 70 years or younger than 18 years

        Diagnosed and/or are taking medications for hypertension (&gt;140/90mmHg)

        Diabetes

        High blood cholesterol

        Heart problems (e.g. arrhythmia, high‐grade stenosis of the carotid artery or carotid sinus
        syndrome)

        Allergy to olive oil or olive oil products

        Lactose intolerance

        Taking omega‐3 supplements in fish oil and vitamins supplements in the last six months.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Applied Sciences, Faculty of Health and Life Sciences, Northumbria University</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE1 8ST</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>November 28, 2019</study_first_submitted>
  <study_first_submitted_qc>December 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 5, 2019</study_first_posted>
  <last_update_submitted>March 16, 2020</last_update_submitted>
  <last_update_submitted_qc>March 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northumbria University</investigator_affiliation>
    <investigator_full_name>Jose Lara Gallegos</investigator_full_name>
    <investigator_title>Senior Lecturer</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

